



MARKET DATA

Symbol:	CTT
Exchange:	AMEX
Share Price (April 23, 2008):	\$ 1.39
Shares Outstanding:	8.2M
Market Cap:	\$ 11.5M

CONFERENCE OBJECTIVES

To create awareness of CTT's portfolio of commercially viable technologies, which exploit the opportunities of the paradigm shift resulting from record high costs of both healthcare and energy, with potential to provide solutions in rapidly growing markets.

To obtain new, innovative technologies to add to CTT's portfolio.

RECENT DEVELOPMENTS

April 25

CTT Signs Agreement for European Distribution of Pain Management Device

April 18

CTT Highlights Pain Management Technology at Annual Meeting

February 13

CTT's Client Grants License for Cognitive Enhancement Pharmaceutical Library

January 22

CTT Reclaims Rights to Sexual Dysfunction Technologies

January 10

CTT Obtains License Rights to Non-Invasive Early-Detection Test for Breast Cancer

FEATURED TECHNOLOGIES

Pain Management Therapy: This US patent pending technology, medically certified in Europe, treats oncological and neuropathic pain through a biophysical rather than biochemical approach. The device is designed to create self-like neurons by applying surface electrodes to the skin to simultaneously treat multiple pain areas. CTT partner GEOMC, formerly Daeyang, is producing the device commercially for worldwide distribution.

Nanotechnology Bone Biomaterial: CTT has exclusive rights to the patented nanoparticle-formulated biomaterial for skeletal bone repair. The flowable, moldable paste forms a solid bone-like structure capable of stabilizing fractured bone within 15 minutes. The technology has superior compressive strength, is machinable and drillable. It can be used for human bones and for dental and veterinary uses. Soteira, Inc. was granted an exclusive license for applications related to the human spine.

Sexual Dysfunction Therapeutic: CTT has exclusive rights to license for development a sexual dysfunction therapeutic. The therapeutic acts on brain receptors to stimulate natural sexual arousal without acting directly on the vascular system, and is effective on both males and females.

Breast Cancer Test: CTT has rights to the patented breast cancer detection device, Early Breastest™, from the research of Milton Schonberger and Dr. Anthony Barbara. The non-invasive technology generates an analysis that detects angiogenesis, using adhesive pads embedded with hundreds of thermistors, micro-thermometers. The Schonberger patent for the world's first disposable thermometer is the basis for this new technology.



Competitive Technologies, Inc.

777 Commerce Drive
Suite 100
Fairfield, CT 06825
(203) 368-6044
www.competitivetech.net



John B. Nano
Chairman, President and CEO

Company Description

Competitive Technologies, Inc., established in 1968, is a full service technology transfer and licensing provider focused on the technology needs of its customers and transforming those requirements into commercially viable solutions. CTT is a global leader in identifying, developing and commercializing innovative technologies in life, electronic, nano, and physical sciences developed by universities, companies and inventors. CTT maximizes the value of intellectual assets for the benefit of its customers, clients and shareholders.